46 related articles for article (PubMed ID: 15235577)
1. [Outcomes of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for 10 patients with myelofibrosis].
Liu HX; Yang J; Jiang JL; Cai Y; Wan LP; Wu L; Shao S; Wang C
Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):225-230. PubMed ID: 29562468
[No Abstract] [Full Text] [Related]
2. Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
Miyao K; Sawa M; Kuwatsuka Y; Ozawa Y; Kato T; Kohno A; Sao H; Nishida T; Iida H; Naito K; Tsurumi H; Taji H; Mizuta S; Kusumoto S; Nakase K; Morishita Y; Kawashima N; Miyamura K; Murata M;
Bone Marrow Transplant; 2016 Jan; 51(1):157-60. PubMed ID: 26437064
[No Abstract] [Full Text] [Related]
3. [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
Yuan J; Ren H; Qiu Z; Li Y; Wang M; Liu W; Xu W; Sun Y; Wang L; Liang Z; Dong Y; Ou J; Wang W; Yin Y; Cen X; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):475-9. PubMed ID: 26134011
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI.
Späth C; Busemann C; Krüger WH
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1981-8. PubMed ID: 24965745
[TBL] [Abstract][Full Text] [Related]
5. Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.
Brandwein JM; Geddes M; Kassis J; Kew AK; Leber B; Nevill T; Sabloff M; Sandhu I; Schuh AC; Storring JM; Ashkenas J
Am J Blood Res; 2013; 3(2):141-64. PubMed ID: 23675565
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
Koreth J; Aldridge J; Kim HT; Alyea EP; Cutler C; Armand P; Ritz J; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2010 Jun; 16(6):792-800. PubMed ID: 20074656
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
11. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
Falda M; Busca A; Baldi I; Mordini N; Bruno B; Allione B; Rambaldi A; Morello E; Narni F; Santarone S; Locatelli F; Bacigalupo A;
Am J Hematol; 2007 Oct; 82(10):863-6. PubMed ID: 17616972
[TBL] [Abstract][Full Text] [Related]
13. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
14. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.
Shapira MY; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Miron S; Zilberman I; Slavin S; Or R
Bone Marrow Transplant; 2004 Jul; 34(2):155-9. PubMed ID: 15235577
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]